vTv Therapeutics Inc.
NASDAQ:VTVTBiotechnology
+$0.50 today
- Market cap
- $64.69M
- Beta
- 0.27
- P/E (TTM)
- 128.7
- EPS (TTM)
- $0.27
Volume 0.02M
Average 0.05M
Financial health
vTv Therapeutics Inc. financial health
Start with the overall verdict and the rule-based risk checks for VTVT, then work through liquidity, debt, balance-sheet quality, and claims on cash.
Financial health snapshot
Debt service and balance sheet cushion look healthy, even if some working-capital ratios deserve context.
Cash & Investments
$98.09M
Debt Cushion
$98.09M
Current Ratio
14.4x
Interest Coverage
Not available
Risk checks
2 of 7 checks flagged
Interest coverage
-507.0×
Passes when: Operating income is at least 1.5 times interest expense.
Share dilution
+48.2% per year
Passes when: Diluted share count grows no more than 2% per year.
Positive equity
Positive
Passes when: Shareholders’ equity is above zero.
Short-term liquidity
14.4×
Passes when: Current assets are at least 1 times current liabilities.
Manageable net debt
Net cash
Passes when: Net debt is below 3 times EBITDA.
Tangible equity base
0.0%
Passes when: Goodwill and intangibles are below 50% of equity.
Altman Z-score trend
-10.00 → 2.76
Passes when: The Z-score is stable or rising, or stays above 2.99.
Financial strength scores
How strong are the fundamentals over time?
Piotroski tests profitability, balance-sheet direction, and efficiency; Altman estimates bankruptcy risk. Compare the current scores with their fiscal-year history.
Financial strength scores
Piotroski F-Score and Altman Z-Score from the latest reported financials
Piotroski F-Score
Weak2 / 9
Nine pass/fail tests of profitability, balance-sheet strength, and efficiency. 8–9 is strong, 0–3 is weak.
Altman Z-Score
Distress zone-0.02
Bankruptcy-risk model. Above 2.99 is the safe zone, 1.81–2.99 the grey zone, and below 1.81 the distress zone.
Score history
Piotroski F-Score and Altman Z-Score recalculated from each fiscal year's statements and year-end market value.
Liquidity
Can it meet short-term obligations?
Check whether cash and current assets cover what falls due within a year without depending on fresh financing.
Cash & Equivalents
$98.09M
Q1 2026
Quick Ratio
14.4x
Q1 2026
Current Ratio
14.4x
Q1 2026
Cash Ratio
14.3x
Q1 2026
Working capital
How quickly does cash come back?
Receivable, inventory, and payable days show how much cash the operating cycle ties up and whether that is changing.
Working capital and cash conversion
Annual days measures from year-end receivables, inventory, and payables against revenue and cost of revenue.
Leverage
How much debt risk sits on the balance sheet?
Review total borrowings, debt relative to equity and assets, and whether operating profit covers interest costs.
Total Debt
$0.00
Q1 2026
Debt/Equity
0.0x
Q1 2026
Debt/Assets
0.0x
Q1 2026
Interest Coverage
—
Q1 2026
Debt service
Can cash flow carry the debt?
Measure debt against EBITDA and free cash flow, see how much is due within 12 months, and follow debt and cash over time.
Debt service capacity
Can operating cash flow carry the debt, and how much is due soon?
Debt and cash over time
Fiscal-year-end borrowings against liquid assets; net debt below zero means net cash.
Balance sheet cushion
How much room is there if conditions weaken?
Extra cash and investments, and the balance of assets against liabilities, give the company room when trading gets harder.
Long-Term Investments
$0.00
Q1 2026
Assets
$98.81M
Q1 2026
Liabilities
$8.85M
Q1 2026
Balance sheet quality
Who funds the assets, and how tangible is the equity?
Split the claims on assets between suppliers, lenders, customers, and shareholders, and see how much equity rests on goodwill and intangibles.
Balance sheet quality
Who funds the assets, and how much of the equity is tangible (Q1 2026).
Competitor health
How does vTv Therapeutics Inc. compare with peers?
Compare leverage, interest coverage, and liquidity ratios with similar companies.
Competitor Health
Peer financial health comparison
| Company | Market Cap | D/E | D/Assets | ND/EBITDA | Int. Cov. | Quick | Current | Cash |
|---|---|---|---|---|---|---|---|---|
Spruce Biosciences, Inc. SPRB:NASDAQ | $124.47M | 0.02 | 0.01 | 1.24 | — | 5.17 | 5.17 | 4.85 |
Outlook Therapeutics, Inc. OTLK:NASDAQ | $100.54M | -0.94 | 1.62 | Net cash | — | 0.31 | 0.38 | 0.18 |
NRx Pharmaceuticals, Inc. NRXP:NASDAQ | $94.82M | -0.04 | 0.05 | 0.26 | — | 0.31 | 0.31 | 0.27 |
Fortress Biotech, Inc. FBIO:NASDAQ | $62.70M | 1.49 | 0.40 | 0.25 | — | 2.30 | 2.49 | 1.60 |
MiNK Therapeutics, Inc. INKT:NASDAQ | $47.66M | -0.36 | 0.36 | 0.66 | — | 1.06 | 1.06 | 1.03 |
Werewolf Therapeutics, Inc. HOWL:NASDAQ | $47.64M | 0.38 | 0.14 | 0.90 | — | 1.62 | 1.62 | 1.60 |
Gain Therapeutics, Inc. GANX:NASDAQ | $44.36M | 0.04 | 0.03 | 1.05 | — | 6.63 | 6.63 | 6.22 |
OS Therapies Incorporated OSTX:AMEX | $34.87M | 0.00 | 0.00 | 9.50 | — | 0.03 | 0.03 | 22.94 |
Questions
Financial health questions
Common questions about VTVT's balance sheet, answered from the reported figures.
Is VTVT's balance sheet healthy?
vTv Therapeutics Inc. (VTVT) has a current ratio of 14.36, a quick read on short-term liquidity.
How leveraged is VTVT?
Debt to equity is 0.00, which helps judge how much financing risk sits on the balance sheet.
Continue the stock analysis
Jump to another research area for this company.